RT Journal Article
SR Electronic
T1 Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253773
DO 10.1101/2021.03.17.21253773
A1 Mark A. Brockman
A1 Francis Mwimanzi
A1 Yurou Sang
A1 Kurtis Ng
A1 Olga Agafitei
A1 Siobhan Ennis
A1 Hope Lapointe
A1 Landon Young
A1 Gisele Umviligihozo
A1 Laura Burns
A1 Chanson Brumme
A1 Victor Leung
A1 Julio S.G. Montaner
A1 Daniel Holmes
A1 Mari DeMarco
A1 Janet Simons
A1 Masa Niikura
A1 Ralph Pantophlet
A1 Marc G. Romney
A1 Zabrina L. Brumme
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253773.abstract
AB Background Several Canadian provinces are extending the interval between COVID-19 vaccine doses to increase population vaccine coverage more rapidly. However, immunogenicity of these vaccines after one dose is incompletely characterized, particularly among the elderly, who are at greatest risk of severe COVID-19.Methods We assessed SARS-CoV-2 humoral responses pre-vaccine and one month following the first dose of BNT162b2 mRNA vaccine, in 12 COVID-19 seronegative residents of long-term care facilities (median age, 82 years), 18 seronegative healthcare workers (HCW; median age, 36 years) and 4 convalescent HCW. Total antibody responses to SARS-CoV-2 nucleocapsid (N) and spike protein receptor binding domain (S/RBD) were assessed using commercial immunoassays. We quantified IgG and IgM responses to S/RBD and determined the ability of antibodies to block S/RBD binding to ACE2 receptor using ELISA. Neutralizing antibody activity was also assessed using pseudovirus and live SARS-CoV-2.Results After one vaccine dose, binding antibodies against S/RBD were ∼4-fold lower in residents compared to HCW (p<0.001). Inhibition of ACE2 binding was 3-fold lower in residents compared to HCW (p=0.01) and pseudovirus neutralizing activity was 2-fold lower (p=0.003).While six (33%) seronegative HCW neutralized live SARS-CoV-2, only one (8%) resident did (p=0.19). In contrast, convalescent HCW displayed 7- to 20-fold higher levels of binding antibodies and substantial ability to neutralize live virus after one dose.Interpretation Extending the interval between COVID-19 vaccine doses may pose a risk to the elderly due to lower vaccine immunogenicity in this group. We recommend that second doses not be delayed in elderly individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2021-HQ-000120 to MAB, ZLB, MGR), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP), and the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (project #40947 to MAB, MN, ZLB; project #41067 to RP). MAB holds a Canada Research Chair, Tier 2, in viral pathogenesis and immunity. ZLB holds a Scholar Award from the Michael Smith Foundation for Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards (protocol H20-03906).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data is available to qualified investigators by request to the corresponding authors. A data transfer agreement may be required.